cls overview infographic a4_infcls0051116
TRANSCRIPT
Patients 172,350+ 277,350+ 890,100+ 99,600+ 1,451,100+
Studies 1,750+ 1,600+ 1,500+ 200+ 5,100+Investigator
Sites 6,300+ 33,900+ 91,750+ 6,600+ 139,200+
Study counts include historical CLS+ LabCorp Clinical Trials data. Investigator site and patient counts include only CLS data. Therapeutic study counts are CLS only.
Source: Internal metrics 2011-2015
Numberof studies
2011-2015
48 of the 50best-selling drugs in 2015 were
developed in partnership with
Covance Central Laboratory Services.
Unparalleled therapeutic experience over the
past 5 years. Over 5,100 studies, more
than 2x as many as any other central lab.
Unique insights in all therapeutic areas...
...and at every step of the process.
PHASE I
IND NDAPHASE II TOTAL
PHASE III PHASE IV
CentralNervous System
820
Oncology
1,266
Endocrine/Metabolic
692
ImmuneSystem
882
InfectiousDiseases
525
YOUR JOURNEY FROMIND TO NDA... AND BEYOND
per day by reducing the risk of delaysto your trial completion milestones
Our on-time delivery can save you
$600,000+
Proven results at every stage of the trial
OUR SOLUTIONS TO MEET YOUR STUDY MILESTONES
START UP
EXECUTION
DELIVERY
BETTER DECISIONS, FASTEROur global automation strategy delivers consistent results.
SAVING SAMPLES MEANS SAVING MONEY Data reconciliation speeds data submissions. Covance delivered 99.4% of data packages on time in 2015.
Reportabletest yields
98.3%
Sample receiptwithin stability
99.2%
You can count on our ability to deliver: Over 2,000,000 shipments to and from over 85 countries each year.
The Americas +1.888.COVANCE (+1.888.268.2623) +1.609.452.4440
Europe / Africa +00.800.2682.2682 +44.1423.500888 Asia Pacific +800.6568.3000 +65.6.5686588
© Copyright 2016 Covance Inc. INFCLS005-1116
Covance Inc., headquartered in Princeton, NJ, USA, is the drug development business of Laboratory Corporation of America Holdings (LabCorp). COVANCE is a registered trademark and the marketing name for Covance Inc. and itssubsidiaries around the world.
Source: LifeScience StrategyGroup survey, 2016
INVESTIGATORS PREFER COVANCE BY 3XMeet your enrollment milestones faster withengaged investigators and on-time kit delivery.